Phase 2 Pancreatic Cancer Trial, Recruiting NCT06050317 Sponsor: Shandong Cancer Hospital and Institute Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06050317
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose general physical condition is rated as fully active or restricted only in physically strenuous activity (this is measured using a standard health performance scale called ECOG, scores 0–1)
  • People who have been confirmed by tissue testing to have locally advanced pancreatic cancer that cannot be removed by surgery
  • People with pancreatic cancer who have not yet received any systemic (whole-body) anti-cancer treatment
  • People whose cancer either started in the pancreas or has at least one measurable tumour area, as defined by standard medical imaging guidelines
  • People who are expected to live for more than 3 months
  • People whose blood test results show that their white blood cells, platelets, and red blood cells are at or above certain minimum levels
  • People whose liver function, kidney function, and certain other blood markers fall within acceptable ranges as determined by standard laboratory tests

Who may not be able to join:

  • People who have been diagnosed with another type of cancer (other than pancreatic cancer) within the past three years
  • People who are currently taking part in another interventional clinical trial, or who have received an experimental drug or used an experimental medical device within the past four weeks
  • People who have previously been treated with certain types of immunotherapy drugs that target the immune system's T-cell pathways (such as anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs)
  • People who have received certain traditional Chinese medicines with anti-cancer indications, or drugs that affect the immune system, within the past two weeks
  • People whose blood, liver, kidney, or blood clotting test results are outside of normal ranges
  • People who have had abnormal function in any major organ within the 14 days before joining the trial
  • People who are pregnant
  • People who are unable or unwilling to understand and sign a written consent form (this may include a legally authorised representative signing on their behalf)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jinbo Yue, dorctor, Shandong Cancer Hospital and Institute

Phone: 0531-67626442

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shandong Cancer Hospital and Institute
Registry
ClinicalTrials.gov
Start date
18 August 2023
Est. completion
18 August 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS; AE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov